17-AAG, an hsp90 inhibitor, inhibits the expression of Akt in fibroblasts, thereby suppressing their proliferation and reducing their migratory capacity, in addition to downregulating type I collagen mRNA and protein expression and inhibiting the TGF-β1/SMAD pathway, which has potential value for keloid therapy (114, 115). This evidence concerns the gene TGFB1 and keloid.